Cardiotoxicity associated with cancer therapy: Pathophysiology and prevention strategies;Cardiotoxicidade associada à terapêutica oncológica: Mecanismos fisiopatológicos e estratégias de prevençã o

Revista Portuguesa de Cardiologia

Volumn 32, Issue 5, 2013, Pages 395-409

  Adão, Rui ^a   De Keulenaer, Gilles ^b   Leite Moreira, Adelino ^a   Braś Silva, Carmen ^a  

^a University of Porto   (Portugal)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Anthracyclines; Cardiomyopathy; Cardiotoxicity; Chemotherapy; ErbB; Radiotherapy; Trastuzumab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; TRASTUZUMAB;

ADVERSE OUTCOME; CANCER CHEMOTHERAPY; CANCER THERAPY; CARDIOLOGIST; CARDIOMYOPATHY; CARDIOTOXICITY; CELL DAMAGE; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG FATALITY; EARLY DIAGNOSIS; HEART FAILURE; HEART MUSCLE CELL; HUMAN; HYPERTENSION; NEOPLASM; PATHOPHYSIOLOGY; PATIENT MONITORING; PRACTICE GUIDELINE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SYSTOLIC DYSFUNCTION; TREATMENT PLANNING;

EID: 84880142554     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.repc.2012.11.002     Document Type: Short Survey

References (100)

1. Minami M, Matsumoto S, Horiuchi H. Cardiovascular side-effects of modern cancer therapy. Circ J. 2010;74:1779-86.
2. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53:2231-47.
3. Raschi E, Vasina V, Ursino MG, et al. Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy. Pharmacol Ther. 2010;125:196-218.
4. Araújo A, Barata F, Barroso S, et al. Cost of cancer care in Portugal. Acta Med Port. 2009;22:525-36.
5. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765-81.
6. Viale PH, Yamamoto DS. Cardiovascular toxicity associated with cancer treatment. Clin J Oncol Nurs. 2008;12:627-38.
7. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: What the cardiologist needs to know. Nat Rev Cardiol. 2010;7:564-75.
8. López Medrano F, Sánchez Muñoz A, Sánchez Sánchez V, et al. Cardiotoxicity of 5-fluorouracil: Ischemia or myocardial toxicity? Rev Clin Esp. 2001;201:106-7.
9. Lestuzzi C. Neoplastic pericardial disease: Old and current strategies for diagnosis and management. World J Cardiol. 2010;2:270-9.
10. Barbey JT, Soignet S. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med. 2001;135:842-3. (Pubitemid 33051273)
11. Eschenhagen T, Force T, Ewer MS, et al. Cardiovascular side effects of cancer therapies: A position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2011;13:1-10.
12. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20:1215-21. (Pubitemid 34177427)
13. Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102:14-25.
14. Lefrak EA, Pitha J, Rosenheim S, et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32:302-14.
15. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity. J Clin Oncol. 2005;23:2900-2. (Pubitemid 46224107)
16. Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23:7820-6. (Pubitemid 46657379)
17. Telli ML, Hunt SA, Carlson RW, et al. Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility. J Clin Oncol. 2007;25:3525-33. (Pubitemid 47310891)
18. Ryberg M, Nielsen D, Skovsgaard T, et al. Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer. J Clin Oncol. 1998;16:3502-8. (Pubitemid 28506760)
19. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:2629-36. (Pubitemid 46179451)
20. Hortobagyi GN, Frye D, Buzdar AU, et al. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer. 1989;63:37-45. (Pubitemid 19031978)
21. Kremer LC, van Dalen EC, Offringa M, et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: Long-term follow-up study. J Clin Oncol. 2001;19:191-6. (Pubitemid 32063496)
22. Sawyer DB, Peng X, Chen B, et al. Mechanisms of anthracycline cardiac injury: Can we identify strategies for cardioprotection? Prog Cardiovasc Dis. 2010;53:105-13.
23. Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses. FASEB J. 1990;4:3076-86.
24. Ito H, Miller SC, Billingham ME, et al. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. Proc Natl Acad Sci USA. 1990;87:4275-9.
25. Jeyaseelan R, Poizat C, Wu HY, et al. Molecular mechanisms of doxorubicin-induced cardiomyopathy. Selective suppression of Reiske iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes. J Biol Chem. 1997;272:5828-32. (Pubitemid 27102415)
26. Lim CC, Zuppinger C, Guo X, et al. Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem. 2004;279:8290-9. (Pubitemid 38294721)
27. Takahashi S, Denvir MA, Harder L, et al. Effects of in vitro and in vivo exposure to doxorubicin (adriamycin) on caffeine-induced Ca2+ release from sarcoplasmic reticulum and contractile protein function in 'chemically-skinned' rabbit ventricular trabeculae. Jpn J Pharmacol. 1998;76:405-13. (Pubitemid 28227083)
28. Lebrecht D, Kokkori A, Ketelsen UP, et al. Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. J Pathol. 2005;207:436-44. (Pubitemid 43025692)
29. Fu M, Matoba M, Liang QM, et al. Properties of G-protein modulated receptor-adenylyl cyclase system in myocardium of spontaneously hypertensive rats treated with adriamycin. Int J Cardiol. 1994;44:9-18. (Pubitemid 24110043)
30. Dodd DA, Atkinson JB, Olson RD, et al. Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model. J Clin Invest. 1993;91:1697-705. (Pubitemid 23127375)
31. De Angelis A, Piegari E, Cappetta D, et al. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation. 2010;121:276-92.
32. Mordente A, Meucci E, Silvestrini A, et al. New developments in anthracycline-induced cardiotoxicity. Curr Med Chem. 2009;16:1656-72.
33. Ganzina F. 4′-epi-doxorubicin, a new analogue of doxorubicin: A preliminary overview of preclinical and clinical data. Cancer Treat Rev. 1983;10:1-22. (Pubitemid 13058185)
34. Ganzina F, Pacciarini MA, di Pietro N. Idarubicin (4- demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies. Invest New Drugs. 1986;4:85-105. (Pubitemid 16163069)
35. Kratz F, Warnecke A, Schmid B, et al. Prodrugs of anthracyclines in cancer chemotherapy. Curr Med Chem. 2006;13:477-523.
36. van Dalen EC, Michiels EM, Caron HN, et al. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010:CD005006.
37. Cortés-Funes H, Coronado C. Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol. 2007;7:56-60. (Pubitemid 47339867)
38. Slingerland M, Guchelaar HJ, Gelderblom H. Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov Today. 2012;17:160-6.
39. Abraham SA, Waterhouse DN, Mayer LD, et al. The liposomal formulation of doxorubicin. Methods Enzymol. 2005;391:71-97. (Pubitemid 40254030)
40. Sessa C, Valota O, Geroni C. Ongoing phase I and II studies of novel anthracyclines. Cardiovasc Toxicol. 2007;7:75-9. (Pubitemid 47339871)
41. Wouters KA, Kremer LC, Miller TL, et al. Protecting against anthracycline-induced myocardial damage: A review of the most promising strategies. Br J Haematol. 2005;131:561-78. (Pubitemid 43899624)
42. Myers C, Bonow R, Palmeri S, et al. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol. 1983;10:53-5. (Pubitemid 13092606)
43. Ladas EJ, Jacobson JS, Kennedy DD, et al. Antioxidants and cancer therapy: A systematic review. J Clin Oncol. 2004;22:517-28. (Pubitemid 41079781)
44. Schuchter LM, Hensley ML, Meropol NJ, et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2002;20:2895-903. (Pubitemid 34651519)
45. Swain SM. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity. Semin Oncol. 1998;25:43-7. (Pubitemid 28460383)
46. Martin M, Esteva FJ, Alba E, et al. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: Review and expert recommendations. Oncologist. 2009;14:1-11.
47. Swain SM, Whaley FS, Gerber MC, et al. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol. 1997;15:1333-40. (Pubitemid 27167364)
48. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-72. (Pubitemid 41464705)
49. Serrano C, Cortés J, de Mattos-Arruda L, et al. Trastuzumab-related cardiotoxicity in the elderly: A role for cardiovascular risk factors. Ann Oncol. 2011;23:897-902.
50. Lee KF, Simon H, Chen H, et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature. 1995;378:394-8.
51. Zhao YY, Sawyer DR, Baliga RR, et al. Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem. 1998;273:10261-9. (Pubitemid 28227629)
52. Ozcelik C, Erdmann B, Pilz B, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci USA. 2002;99:8880-5. (Pubitemid 34693652)
53. Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002;8:459-65. (Pubitemid 34546747)
54. Lemmens K, Doggen K, de Keulenaer GW. Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease: Implications for therapy of heart failure. Circulation. 2007;116:954-60. (Pubitemid 47300920)
55. Perik PJ, de Vries EG, Gietema JA, et al. Serum HER2 levels are increased in patients with chronic heart failure. Eur J Heart Fail. 2007;9:173-7. (Pubitemid 46394075)
56. Jabbour A, Hayward CS, Keogh AM, et al. Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur J Heart Fail. 2011;13:83-92.
57. Di Cosimo S. Heart to heart with trastuzumab: A review on cardiac toxicity. Target Oncol. 2011;6:189-95.
58. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733-43. (Pubitemid 46021510)
59. Sliwkowski MX, Lofgren JA, Lewis GD, et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol. 1999;26:60-70. (Pubitemid 29411434)
60. Shell SA, Lyass L, Trusk PB, et al. Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells. Cell Cycle. 2008;7:1769-75. (Pubitemid 351988742)
61. Spector NL, Yarden Y, Smith B, et al. Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proc Natl Acad Sci USA. 2007;104:10607-12. (Pubitemid 47185712)
62. Albini A, Cesana E, Donatelli F, et al. Cardio-oncology in targeting the HER receptor family: The puzzle of different cardiotoxicities of HER2 inhibitors. Future Cardiol. 2011;7:693-704.
63. Nakagami H, Takemoto M, Liao JK. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol. 2003;35:851-9. (Pubitemid 36773597)
64. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114:2474-81. (Pubitemid 44901520)
65. Lemarié CA, Paradis P, Schiffrin EL. New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone. J Mol Med (Berl). 2008;86:673-8.
66. Zeglinski M, Ludke A, Jassal DS, et al. Trastuzumab-induced cardiac dysfunction: A 'dual-hit'. Exp Clin Cardiol. 2011;16:70-4.
67. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006;24:2786-92. (Pubitemid 46630577)
68. Glück S, McKenna Jr EF, Royce M. XeNA: Capecitabine plus docetaxel, with or without trastuzumab, as preoperative therapy for early breast cancer. Int J Med Sci. 2008;5:341-6.
69. Castrellon AB, Glück S. Adjuvant therapy for HER2 positive breast cancer: Are anthracyclines still necessary? Clin Adv Hematol Oncol. 2008;6:666-72.
70. Chari RV. Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41:98-107.
71. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68:9280-90.
72. Burris 3rd HA, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29:398-405.
73. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354:809-20. (Pubitemid 43290919)
74. Muss HB, Thor AD, Berry DA, et al. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994;330:1260-6.
75. Di Leo A, Gancberg D, Larsimont D, et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res. 2002;8:1107-16. (Pubitemid 34517647)
76. Villman K, Sjöström J, Heikkilä R, et al. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer. Acta Oncol. 2006;45:590-6. (Pubitemid 44167211)
77. Bartlett JM, Munro A, Cameron DA, et al. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol. 2008;26:5027-35.
78. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007;116:e148-304.
79. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis, and management. Circulation. 2004;109:3122-31.
80. Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: A prospective study. J Cancer Res Clin Oncol. 2008;134:75-82. (Pubitemid 350060687)
81. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99:1232-9. (Pubitemid 47299901)
82. Zambelli A, della Porta MG, Eleuteri E, et al. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. Breast. 2011;20:176-83.
83. Guglin M, Aljayeh M, Saiyad S, et al. Introducing a new entity: Chemotherapy-induced arrhythmia. Europace. 2009;11:1579-86.
84. Onaitis M, D'Amico T, Zhao Y, et al. Risk factors for atrial fibrillation after lung cancer surgery: Analysis of the Society of Thoracic Surgeons general thoracic surgery database. Ann Thorac Surg. 2010;90:368-74.
85. Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol. 2009;20:807-15.
86. Scartozzi M, Galizia E, Chiorrini S, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol. 2009;20:227-30.
87. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632-4. (Pubitemid 46680709)
88. Rodeghiero F, Elice F. Thalidomide and thrombosis. Pathophysiol Haemost Thromb. 2003;33:15-8. (Pubitemid 37490521)
89. Hirsh J. Risk of thrombosis with lenalidomide and its prevention with aspirin. Chest. 2007;131:275-7. (Pubitemid 46123003)
90. Deitcher SR, Gomes MP. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer. 2004;101:439-49. (Pubitemid 38970595)
91. Ewer MS, Glück S: A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health. Cancer. 2009;115:1813-26.
92. Yusuf SW, Sami S, Daher IN. Radiation-induced heart disease: A clinical update. Cardiol Res Pract. 2011;2011:317659.
93. Veinot JP, Edwards WD. Pathology of radiation-induced heart disease: A surgical and autopsy study of 27 cases. Hum Pathol. 1996;27:766-73. (Pubitemid 26287216)
94. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA. 1993;270:1949-55. (Pubitemid 23312611)
95. Kettenhofen R, Bohlen H. Preclinical assessment of cardiac toxicity. Drug Discov Today. 2008;13:702-7.
96. Barros TP, Alderton WK, Reynolds HM, et al. Zebrafish: An emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery. Br J Pharmacol. 2008;154:1400-13.
97. Shankar SM, Marina N, Hudson MM, et al. Monitoring for cardiovascular disease in survivors of childhood cancer: Report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics. 2008;121:e387-96. (Pubitemid 351198462)
98. Trachtenberg BH, Landy DC, Franco VI, et al. Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatr Cardiol. 2011;32:342-53.
99. Altena R, Perik PJ, van Veldhuisen DJ, et al. Cardiovascular toxicity caused by cancer treatment: Strategies for early detection. Lancet Oncol. 2009;10:391-9.
100. Lester SJ, Tajik AJ, Nishimura RA, et al. Unlocking the mysteries of diastolic function: Deciphering the Rosetta Stone 10 years later. J Am Coll Cardiol. 2008;51:679-89. (Pubitemid 351221211)